Winnipeg, Canada
Winnipeg, Canada
SEARCH FILTERS
Time filter
Source Type

News Article | May 17, 2017
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - May 17, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation" or "Kane Biotech") is pleased to announce its Q1 2017 Financial Results. All amounts referenced herein are in Canadian dollars. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release may constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Corporation's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Corporation's filings with Canadian securities regulatory authorities, as well as the Corporation's ability to anticipate and manage the risks associated with the foregoing. The Corporation cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Corporation's forward-looking statements to make decisions with respect to the Corporation's, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement. All Rights Reserved 2017.


WINNIPEG, MANITOBA--(Marketwired - July 24, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech") today announced it has paid out all its outstanding debt. This includes its $500,000 convertible note and $400,000 bridge loan. Mark Ahrens-Townsend, President and CEO of Kane Biotech, commented, "The debt proceeds provided value to the Company, however, many prospective investors as well as existing shareholders have voiced their preference for a clean balance sheet, free of debt having priority and security over the common shares of the Company. I am very pleased to say Kane Biotech is now completely debt free." The Company also announced it has granted an aggregate of 915,000 stock options at an exercise price of $0.30 per common share to directors, management and employees of the Company. The options are pursuant to the Company's stock option plan and are subject to TSX Venture Exchange acceptance. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to resale restriction for a period of four months from the date of the grant. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE". Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | June 1, 2017
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - June 1, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech") today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering") of up to 33,333,333 units ("Units") at a price of $0.12 per Unit for gross proceeds of up to $4,000,000. Each Unit shall be comprised of one common share of the Company (a "Share") and one Share purchase warrant (a "Warrant"). Each Warrant shall entitle the holder thereof to purchase one Share at a price of $0.18 per Share for a period of 18 months from the date of issuance of the Warrant. The closing of the Offering is scheduled for July 14, 2017. The Company reserves the right to call the Warrants, at their exercise price of $0.18 per Warrant, in the event that the Shares have traded for ten (10) consecutive trading days at a closing price at or exceeding $0.25 per Share. If the Company wishes to call the Warrants, the Company must provide written notice to the holders of the Warrants that it is calling the Warrants. Investors will have thirty (30) days from the date of such notice to exercise the Warrants and, in the event that any Warrants are not exercised, such Warrants shall be cancelled. Insiders of the Company, including the Chairman and the CEO, have informed the Company that they will be subscribing for a minimum of $1,500,000 (12,500,000 Units) of the Offering. Certain persons may assist the Company by introducing potential subscribers for the Offering and, subject to compliance with applicable legislation, may be entitled to receive a finder's fee and/or broker warrants in such amounts and on such terms as may be determined by the Company. The net proceeds of the Offering will be used for business development, technology and product commercialization, patent and trademark filings, regulatory expenses, clinical trials and general working capital. The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release may constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Company's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Company's filings with Canadian securities regulatory authorities, as well as the Company's ability to anticipate and manage the risks associated with the foregoing. The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Company's forward-looking statements to make decisions with respect to the Company's, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement.


News Article | June 27, 2017
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - June 27, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech") today announced that it has received a loan (the "Loan") in the amount of $400,000 from Individual Investment Corporation, an arm's length third-party lender (the "Lender"). The Loan bears interest at 12% per annum and is repayable after two months. The Corporation has also paid a one-time document review fee of $8,000 to the Lender as additional consideration for the provision of the Loan to the Company. The Loan has been guaranteed by Richard Renaud, the father of Philip Renaud, the Chairman and a significant shareholder of the Company. It is anticipated that the Loan will be repaid following completion of the current private placement offering of units (comprised of common shares and warrants) by the Company, which is scheduled to close on July 14, 2017. As consideration for guaranteeing the Loan, Richard Renaud has been issued 800,000 share purchase warrants of the Company, each of which entitles Mr. Renaud to purchase one Common Share at a price of $0.18 per Common Share for a period of one year from the date of issuance of the Warrants. The Warrants, and any Common Shares issuable upon exercise thereof, are restricted from transfer for a period of four months in accordance with applicable securities laws. The proceeds of the Loan will be used as a bridge to the completion of the current private placement offering by the Company and for general working capital purposes. The closing of the Loan transaction is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange. About Kane Biotech Inc. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE". Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains certain statements regarding the use of proceeds of the Loan and the timing of repayment of the Loan which constitute forward-looking information. The forward-looking information is subject to certain risks and uncertainties which could result in actual events or results differing materially from the forward-looking statements, including: (a) a change in the business or operations of the Company that may result in a change in the proposed use of the proceeds of the Loan; and (b) the inability of the Company to complete its current private placement offering which would negatively impact the ability of the Company to repay the Loan. The Company undertakes no obligation to update or revise any forward-looking statement contained herein.


Compositions comprising one or more chelating agents and optionally zinc ion salts are used to inhibit the growth or biofilm formation in bacteria associated with personal care products such as ophthalmic, pedicure, manicure or podiatric solutions. The compositions of the present application can also comprise gelling agents, antimicrobials, antibiotic or a pH adjuster. The compositions may be in the form of a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, soap and a cleaner.


News Article | May 11, 2017
Site: www.marketwired.com

WINNIPEG, MANITOBA--(Marketwired - May 11, 2017) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation" or "Kane Biotech") is pleased to provide an update on its business activities and intellectual property achievements. The Corporation continues to focus the majority of its resources on the development and commercialization of its technologies and products for the companion animal oral care market. Pets have become part of the family and our vision in the companion pet market is to offer the premier program of quality oral care products based on science with proven efficacy and certified safety. The goal is for dog and cat pet owners around the world to have their pets enjoy healthier lives and live longer as valued members of their families. As the Corporation moves forward our vision will propagate further into other areas of animal health, human health and commercial, institutional and industrial facilities where we know Kane Biotech's anti-biofilm technologies are needed more than ever in the battle against the evolution of bacteria and their developing resistances to many antibiotic/antimicrobial approaches. Kane Biotech's strategy is to advance our technologies and products and then license them worldwide to industry leaders. Kane Biotech's recently announced exclusive licensing and distribution agreement with Dechra Veterinary Products LLC for the North American veterinary market is the Corporation's first commercial licensing deal. Our objective is to find and sign many more agreements like this over the coming months and years. Below are some highlights of the Corporation's recent progress: Kane Biotech's bluestem™ brand of companion pet oral care products are now being sold in over 1,000 pet specialty stores across Canada and the United States. Kane Biotech is actively supporting Dechra in the transition and promotion of the Corporation's StrixNB® veterinarian oral health care technology. In support of developing its business opportunities in veterinary and pet specialty Kane Biotech has recently attended the following industry events: There has been strong international interest in both StrixNB and bluestem at the major veterinary and pet specialty conferences in Orlando and Las Vegas which the Corporation is actively pursuing. In Q2 and Q3 2017 Kane Biotech will be exhibiting and promoting its bluestem companion pet oral care products at the following events. Everyone is encouraged to come visit with us. In addition, Kane Biotech will be supporting Dechra at the Canadian Veterinary Medical Association conference in Charlottetown, PEI July 13-16. The following 11 patents have been issued from the United States, European, Japanese and New Zealand Patent and Trademark Offices. Kane Biotech now has 33 issued patents and 37 pending. In addition, Kane Biotech has been informed that the following 3 patents are soon to be issued: The bluestem and coactiv+ registered trademarks have been granted in Europe and registered in classes 3, 5, 31, 35, 39, 40 and 44. These marks can be used in wound care products for pet and human uses such as shampoo, otic drops, wound spray and gels, bandages, wipes, lotions and creams. The marks can also be used for food additives, nutritional care products, pill supplements, treats, and food and oral care products such as water additive or spray. The wholesale and retail services, distribution, and custom manufacturing for these products is covered by these trademarks. Using the marks in the operation and maintenance of an internet website has also been accepted. These marks are pending in Canada and the United States. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications. Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending, trade secrets and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE". The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release may constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Corporation's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Corporation's filings with Canadian securities regulatory authorities, as well as the Corporation's ability to anticipate and manage the risks associated with the foregoing. The Corporation cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Corporation's forward-looking statements to make decisions with respect to the Corporation's, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement. All Rights Reserved 2017.


Compositions comprising one or more chelating agents and optionally zinc ion salts are used to inhibit the growth or biofilm formation in bacteria associated with personal care products such as ophthalmic, pedicure, manicure or podiatric solutions. The compositions of the present application can also comprise gelling agents, antimicrobials, antibiotic or a pH adjuster. The compositions may be in the form of a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, soap and a cleaner.


The present invention provides compositions comprising an antibiofilm enzyme, a soluble -N-acetylglucosaminidase similar to the dspB gene (DispersinB), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using soluble -N-acetylglucosaminidase based antimicrobial compositions.


Patent
Kane Biotech | Date: 2014-05-01

The present invention provides novel compositions comprising: (a) a metaperiodate and (b) chlorhexidine or a chlorohexidine salt and uses thereof for the preparation of devices, and in particular medical devices, susceptible to colonization by biofilm forming bacteria.


Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.

Loading Kane Biotech collaborators
Loading Kane Biotech collaborators